Agoracom Blog Home

Posts Tagged ‘MMRP’

PhytoPain Pharma Files Clinical Trial Application (CTA) for a Topical Product for the Treatment of Chemotherapy-Induced Neuropathic Pain $

Posted by AGORACOM-JC at 8:54 AM on Wednesday, June 15th, 2016


  • Announced that it has filed a Clinical Trial Application (CTA) with Health Canada for PhytoPain Topical Gel Relief (PPTGR), a locally administered therapeutic for the treatment of chemotherapy-induced neuropathic pain (CINP)
  • Upon approval of the CTA, the Company plans to initiate a double-blind, randomized, cross-over, placebo-controlled clinical study with PPTGR in late 2016 and expects to report initial clinical data from the trial in late 2017

OTTAWA, ONTARIO–(June 15, 2016) – PhytoPain Pharma (PPP) Inc., a subsidiary of GrowPros Cannabis Ventures Inc. (“GrowPros” or the “Company” or “GCI“) (CSE:GCI), today announced that it has filed a Clinical Trial Application (CTA) with Health Canada for PhytoPain Topical Gel Relief (PPTGR), a locally administered therapeutic for the treatment of chemotherapy-induced neuropathic pain (CINP). Upon approval of the CTA, the Company plans to initiate a double-blind, randomized, cross-over, placebo-controlled clinical study with PPTGR in late 2016 and expects to report initial clinical data from the trial in late 2017.

CINP is a common adverse effect of cancer therapy and a frequent reason why cancer patients stop their treatment early. For some patients, the severity of the symptoms can be reduced by lowering the dose of chemotherapy or temporarily stopping it. In other patients, the symptoms of CINP may last for months or years after the cancer therapy has stopped. CINP symptoms are managed using the same analgesics used to manage other types of neuropathic pain. Some of these analgesics also cause intolerable side effects in patients. The use of a topical counterirritant may help reduce the symptoms of CINP and avoid exposing some patients to oral neuropathic pain analgesics.

According to Dr. Guy Chamberland, the Company’s Chief Scientific Officer, “PPP is developing this topical product to provide cancer patients a safer, natural and more tolerable alternative in the management of CINP”. The development of the PPTGR product is in line with PPP’s strategy to bring an integrative medical approach for cancer patients suffering from pain. “The demonstration of the safety and efficacy of botanical drugs including cannabis for pain management is a critical step in the development of an evidence-based approach to integrative medical care. PPP intends on working with physicians to demonstrate that PPTGR can be safely used as an adjunct to inhalation and oral medical marijuana for the reduction of pain in cancer patients. Physicians need additional drugs that can help reduce the amount of narcotics required to manage pain while minimizing the risk of psycho active effects or tolerance to opioids, cannabis, and other narcotics commonly prescribed to patients. The intention is to develop PPTGR, and other botanical-based drugs, as adjuncts to the standard of care,” stated Dr. Chamberland.

PPTGR is a counterirritant topical gel that conforms to the Natural and Non-prescription Health Products Directorate (NNHPD) monograph. However, the intended use of counterirritant products under the NNHPD monograph does not include the temporary relief of CINP. PPP is launching a clinical trial to demonstrate the safety and efficacy of PPTGR in cancer patients with CINP and work with medical oncologists to integrate the use of PPTGR in the management of CINP.

International research indicates that 60% of patients undergoing chemotherapy will suffer from varying degrees of CINP during their treatment. PPP believes it can demonstrate increased symptom alleviation using natural based agents and mixtures as opposed to the synthetic alternatives. “PPP was created to conduct cannabinoid and medicinal plant based research with the goal of developing over-the-counter products for consumers and prescription drug products for physicians that can be distributed through the existing pharmaceutical infrastructure. This submission is the first step in the growth of our vision,” commented CEO Ryan Brown.

CINP Market Size and comparison products


There were an estimated 15.2 million cancer cases globally in 2014 according to the International Agency for Research on Cancer (IARC) with projections of 17.1 million cases in 2020. Roughly 25%-30% of cancer patients receive chemotherapy, and of those patients, 70%-80% experience a form of CINP. The global CINP market saw estimated revenue of $1.3 billion in 2014 with a projected 5.7% compounded annual growth rate through 2020 as cancer rates climb with growing, aged populations. Of the products available Oral delivery drug of dronabinol which is comprised of synthetic cannabinoids had sales of $110M in 2014. Similar to other mainly orally administered cannabinoids, results in relatively low bioavailability, coupled with irregular pharmacokinetics secondary to absorption variability and first-pass metabolism by the liver, complicated by the need for multiple dosages per day. In addition, many patients report nausea and/or vomiting as a side-effect related to the drug. (NEMUS BIO SCIENCE)

Many studies have concluded that natural cannabinoids offer a safer, more effective solution than their synthetic counterparts. A recent article entitled Comparison of Outcome Expectancies for Synthetic Cannabinoids and Botanical Marijuana, from The American Journal of Drug and Alcohol Abuse, concluded that given growing public acceptance of recreational and medical marijuana, coupled with negative perceptions and increasing regulation of synthetic cannabinoid compounds, botanical marijuana is likely to remain more available and more popular than synthetic cannabinoids.

PPP is proud to position itself as a leader in the development of natural pharmaceuticals derived Cannabis and other medicinal plants,” commented CEO Ryan Brown.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

GrowPros Cannabis Ventures Inc.
Ryan Brown
Chief Executive Officer
(613) 421-8402

GrowPros Cannabis Ventures Inc.
Andre Audet
Executive Chairman
(613) 421-8402

GrowPros Cannabis Ventures Inc.
Dr. Guy Chamberland
Chief Scientific Officer and Regulatory Affairs
(514) 220-9225

Enertopia Announces Corporate Update, Comments on Federal Court Injunction

Posted by AGORACOM-JC at 7:32 AM on Monday, March 24th, 2014

Vancouver, BC—Enertopia Corporation (ENRT) on the OTCBB and (TOP) on the CSE (the “Company” or “Enertopia”) announces the following Corporate update with respect to the Canadian Federal Court injunction issued Friday March 21. Readers should be advised that the information below is believed to be correct although the case has evolved quickly and may change.

The injunction exempts existing patients currently licensed to possess and grow medical marijuana, from compliance with the new Health Canada regulations for commercial growers that will continue to take effect for those commercial growers, on April 1. The injunction does not affect the new licensing system. The injunction is temporary – for the existing patients, it preserves the status quo only until a legal ruling is produced in their legal case with the government of Canada. News reports suggest that legal case is expected to provide a ruling within one year.

The injunction suggests that Enertopia’s partially-owned partner, The World of Marihuana Productions Ltd, will be allowed to continue to grow for their patients while awaiting for the Health Canada site inspection under the new Marihuana for Medical Purposes Regulations, (MMPR) and for so long as the injunction remains in effect.

The injunction also suggests that Enertopia’s partially-owned partner, The Green Canvas Ltd., will also be allowed to continue to grow for their patients even as they upgrade their facilities to be compliant under the new MMPR system.

The court injunction is good news for medical marihuana patients and the producers that currently supply them. It allows patients access to the medical cannabis they need and allows current producers the ability to meet their patient’s needs, while allowing the current producers to keep their medical marihuana strains.

Health Canada was quoted as saying “While the Courts have said there must be reasonable access to marijuana for medical purposes, Health Canada’s goal is to treat dried marijuana as much as possible like other narcotic drugs used for medical purposes. The Marihuana for Medical Purposes Regulations are intended to provide reasonable access for those Canadians who need access to dried marijuana for medical purposes with the support of a health-care practitioner, while protecting public safety.”

The Court ruled in favor of the new smaller patient limit as set down in the new (MMPR) regulations with patients being restricted to possessing 150 grams of dried marijuana, which is a limit set by the new (MMPR) regulations.

Health Canada further stated “Health Canada is committed to the implementation of the Marijuana for Medical Purposes Regulations in order to provide Canadians reasonable access to dried marijuana for medical purposes, while protecting public safety.”
“Enertopia believes in the provision of affordable, safe, regulated, high quality medicinal marihuana for all medical marihuana patients not only in Canada but around the World wherever permitted by law. We are seeing daily, the benefits medical cannabis have with helping people regain quality of life. Through no fault of their own – because of disease, work place accidents or automobile accidents – and with the judicious use of medical cannabis as a pain relief medication, many patients have reported relief they have been unable to obtain through any other means. We look forward to complying with and working with Health Canada and all applicable regulations during this period of transition” Stated President Robert McAllister

About Enertopia

Enertopia’s shares are quoted in Canada with symbol TOP in the United States with symbol ENRT. For additional information, please visit or call Dale Paruk, President, Coal Harbor Communications Ltd. at 1.604.662.4505

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, evaluation of clean energy projects, Oil & Gas Projects, Medical Marihuana Projects  for participation and/or financing, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions that are forward-looking statements.  Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements., foreign exchange and other financial markets; changes of the interest rates on borrowings; hedging activities; changes in commodity prices; changes in the investments and exploration expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Enertopia Corporation operates.  The User should refer to the risk disclosures set out in the periodic reports and other disclosure documents filed by Enertopia Corporation from time to time with regulatory authorities.  There is no assurance that the Company will be successful in completing any anticipated financing and or its joint Venture partners will receive their Health Canada license under the new regulations or any technology will result in future sales.


The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release

Start your small cap medical marijuana research in the AGORACOM Small Cap Medical Marijuana Stocks Gateway

Financing abounds for medical marijuana startups

Posted by AGORACOM-JC at 9:15 AM on Friday, March 14th, 2014

Financing abounds for medical marijuana startups

All of the medical marijuana producers approved by Health Canada or in the approval process say they’d been approached with multiple financing offers.


Tweed Inc. workers tend to medical marijuana plants at a new commercial operation set up inside a former Hershey’s chocolate factory in Smiths Falls, Ontario, an hour’s drive from Canada’s capital Ottawa, on February 4, 2014. AFP PHOTO/MICHEL COMTE

By: Business reporter, Published on Thu Mar 13 2014

Canada’s new medical marijuana industry is set to make history on the Toronto Stock Exchange.

Tweed Inc., among the first ten companies licensed by the federal government to produce and distribute pot, is in the final stages of approval for a listing on the TSX Venture Exchange.

The firm has a ticker secured — TWD — chosen because fertilizer manufacturer Potash Corp. has long held the ticker POT, joked chairman Bruce Linton.

If it is granted the listing it will become the country’s first public medical marijuana company with an opening share price just below $1, he said.

With over $10 million in private financing, Tweed is housed in the old Hershey’s plant in Smiths Falls and on track to produce 25 different strains of medical marijuana ranging in price from $5 to $12 a gram.

The company hopes to capture a healthy slice of the $1.3-billion medical marijuana industry Health Canada forecasts by 2024. And that’s worth the scrutiny and paperwork of an IPO, said Linton.

“We thought it was an important step to give another level of credibility to what we’re doing as a differentiator in terms of professionalism,” he explained.

Under Canada’s new Marihuana for Medical Purposes Regulations (MMPR), which roll out completely April 1, the government appoints and oversees producers. The old guidelines allowed users to grow their own medical marijuana or purchase it from the government.

The cost for staff and facilities to meet Health Canada’s requirements is substantial, say licensees.

“To build up a capacity to produce large quantities, and test the product, and have a quality, secure operation, that requires significant dollars,” said Bedrocan Canada CEO Marc Wayne.

“You’re moving out of the kind of handmade grow ops in days gone by. This is a much more sophisticated industry.”

Fortunately, startup money abounds. All the approved or pending producers the Star spoke with said they’d been approached with multiple offers by financiers.

Venture capitalist Kevin O’Leary may yet be among them. In a recent CNBC appearance, the investor of Dragon’s Den fame raved about the burgeoning U.S. industry where $14 million (U.S.) of recreational pot was sold in Colorado in January.

“For me as an investor, this is like getting an opportunity to get into alcohol after prohibition just ended,” he said on Squawk Box. “This is going to be a massive multi-billion dollar business, regulated and taxed by the government…. I really like the margins in this business – it is phenomenal,” he said.

However, with these changes only happening at the state level —Washington is next to allow recreational pot — O’Leary fears running afoul of territorial rules.

“If I were to invest in two deals I’ve been looking at in Colorado right now I could run into jurisdictional problems as an investor in another state where it’s illegal,” he said.

The Montreal native needs to look closer to home.

“Since we became licensed, I’ve received quite a number of calls, both from individuals and from bankers wanting to talk to me about financing or investing or even going public,” said Neil Closner, MedReleaf CEO.

“This is an extremely exciting, interesting time for bankers in Canada, because there really isn’t a huge healthcare entrepreneurial base in this country; mostly because the government controls healthcare.”

MedReleaf doesn’t have designs on the TSX though.

“Being a public company has its pros, but it involves a lot of work in terms of public reporting and news releases and regulations,” said Closner. “We’d rather focus on growing and treating our patients.”

Mark Gobuty, CEO of The Peace Naturals Project, has a similar outlook: “We think there’s going to be a significant evolution for this industry. We need to be nimble and responsive, both to our clients and to the regulator, and we need to be privately held, with a low amount of shareholders, for really important decisions.”

One publicly-traded Canadian company has their sights on ancillary industries rather than growers or producers.

“There are just a lot of companies rushing into that space,” said Harry Barr, CEO of Vancouver-based Next Gen Metals Inc. “Part of my fear is that there’s a limited amount of patients. I see us financing the companies that do the lights, the fertilizer, the seed, the sophisticated equipment that would go in there. To use a mining analogy, I want to sell them the picks and shovels.”

The long time mining executive, who is diversifying into medical marijuana and industrial hemp to buoy a mining slump, said Next Gen is currently reviewing 45 proposals.


Start your small cap medical marijuana research in the AGORACOM Small Cap Medical Marijuana Stocks Gateway